Some success has been demonstrated using percutaneous electrical nerve stimulation (PENS) to treat trigeminal-mediated headshaking (TMHS) in horses. The aim of this study is to determine whether electroacupuncture (EA) can provide similar remission from the pain of this debilitating condition. EA is less invasive than PENS and can be carried out in the stable yard without the need for a hospital setting and expensive equipment. Six horses and ponies showing clinical signs of headshaking were treated with electroacupuncture of the infraorbital nerve under light sedation. The nerve was stimulated with alternating 2 and 80 Hz frequencies for a period of 25 min with the current adjusted so that there was visible twitching of the nostrils and/or lips. Follow-up treatments were given when the signs recurred or 4-7 days later if there was no initial response. The procedure was well tolerated by all the horses. Once a response was achieved, the period of remission often increased with subsequent treatments. Median remission time for the first treatment was 5.5 days (mean 7.6 days, range 0-13 days, n = 6). second treatment 8.5 days (mean 10.6 days, range 7-21 days, n = 6), third treatment 18 days (mean 28.8 days, range 6-71 days, n = 6), fourth treatment 47.5 days (mean 10 weeks, range 11 days-23 weeks, n = 6), fifth treatment 13 weeks 5 days (mean 18 weeks 5 days, range 5 weeks-46 weeks, n = 5), sixth treatment 24 days (mean 26 days, range 13-41 days, n = 3). The three horses that started treatment in 2015 received a single treatment in April or May of 2016 and were still asymptomatic at the end of the study period in October 2016. It was concluded that EA of the infraorbital nerve is an effective and well-tolerated treatment for the management of horses considered to be experiencing trigeminal-mediated headshaking.
Introduction
The syndrome termed headshaking (HS) has a characteristic and well-recognised clinical presentation that is thought to be attributable to involvement of the trigeminal nerve. It has been suggested that the condition is similar to trigeminal neuralgia in man (Cook 1980; Mair 1999; Newton et al. 2000) . The human disorder is characterised by episodic, intermittent or persistent, mild or severe tingling, burning, stabbing or shooting electric shock-like pain in the facial region, which is triggered by relatively minor, often specific facial, nasal or oral stimuli. It is suggested that the equine condition is similar (Newton et al. 2000) accounting for the clinical signs observed in horses (Pickles et al. 2014) . Nerve conduction studies show that affected horses have a lower stimulus threshold to trigger sensory nerve action potentials in the maxillary branch of the trigeminal nerve than healthy horses (Aleman et al. 2013; Aleman et al. 2014) .
Electroacupuncture (EA) has been successfully used to treat chronic nerve/neuropathic pain in horses and man (White et al. 2001; Xie et al. 2005 ). Robert 's et al. (2016) described the use of PENS to treat TMHS in horses. The purpose of this study was to determine whether EA provided sufficient relief to recommend as a first line treatment for trigeminal-mediated (TM) HS. To the author's knowledge there are no previous scientific reports of the specific use of EA for the treatment of TMHS in horses.
Electroacupuncture and percutaneous electrical nerve stimulation are similar (Cummings 2001) ; both modulate perception of afferent nociceptive stimuli by inhibiting afferent pain signals and by activation of descending inhibitory pathways. The low pulse rate of 2 Hz induces encephalins and acts on l and d receptors providing analgesia, whist the higher pulse rates of 80-100 Hz release dynorphins and act on j receptors (Han 2003) . This combination of frequencies is more effective than a single constant current. More detailed information on the mechanisms of EA on persistent and neuropathic pain are described by Kim et al. (2013) and Zhang et al. (2014) .
Three of the horses in the current study were sensitive to sunlight so the owners were asked to use protective UV blocking face masks and/or nose nets when they were turned out or exercised. Previous studies have demonstrated that in 50-70% of affected horses there is a significant decrease in clinical signs when using these (Mills and Taylor 2003) . Horses 1, 2 and 6 also wore them in the stable. It has been postulated that photic stimulation of the optic nerve by sunlight causes cross-activation of the maxillary branch of the trigeminal nerve (Madigan et al. 1995) . In addition to reflecting UV light, the effect of the face mask and nose net is considered to be due to stimulation of touch and pressure receptors, the axons of which synapse with the terminals of the small unmyelinated true pain C fibres, subjecting them to presynaptic inhibition (King 1999) . They also give some protection from wind, dust, pollen and thermal radiation from the sun. Full resolution of signs using just a nose net or face mask is rare (Pickles et al. 2014) , and only one of the six horses in this study (Horse 4) showed an adequate response.
Materials and methods
The study was completed over a 19-month period and included four horses and two ponies ( Table 1) . For inclusion they were considered to be trigeminal-mediated headshakers by the primary veterinary surgeon or referral practice and the author. Prior to inclusion each horse underwent a dental and oral examination plus nasopharyngeal endoscopy including examination of the guttural pouches in order to rule out as far as possible the presence of dental issues, tumours, infection or a foreign body. In addition, Horse 3 had dental radiography and a computed tomography scan was performed on Horse 6. All had negative findings with these diagnostic procedures and were showing clinical signs of headshaking at the time of presentation for EA. In the 19-month period no horses were excluded from the study. All horses underwent a comprehensive clinical examination including moving in hand, on the lunge and ridden if appropriate, and a detailed medical history was obtained ( Table 2) . Headshaking grades at rest and at exercise were recorded for each horse and the grading system of 0-3 explained to the owners ( Table 3) . When possible, a video recording was made of the horse at exercise.
Assessment was made of the fit of the bridle and saddle with ridden horses. Any dental, tack or musculoskeletal issues were addressed prior to commencement of treatment in case they were contributory factors to the headshaking.
Procedure
Each horse was sedated with a combination of detomidine hydrochloride 10 lg/kg bwt (Domosedan) 1 and butorphanol
. This is the manufacturer's recommendation for light sedation, but a reduced dose was often adequate. Whilst under sedation, the horse's head was rested on a plastic covered polystyrene block or bedding bales padded with a soft blanket. Care was taken to ensure that the patient's position was comfortable with the head in a neutral position.
The left side of the face was treated first. There was no need for the site to be clipped or scrubbed provided the horse's skin was clean and dry. The infraorbital nerve was palpated and a sterile Chinese style acupuncture needle (0.3 9 25 mm with a coiled copper handle with guide tube 3 ) was inserted through the skin and slid under the nerve into the fascia between the nerve and the underlying periosteum 2-3 cm rostral to the infraorbital foramen. A variety of acupuncture needle types and sizes were tested, but early in the case series it was determined that inserting a 0.3 9 25 mm sterile Chinese acupuncture needle 3 in a medial to lateral and rostral direction minimised the risk of the needle becoming displaced during the procedure. A second needle (Seirin L type needle, size no 8, 0.3 9 50 mm 3 ) was placed in the brachiocephalic muscle at the base of the horse's neck on the same side.
A Cefar ACUS 4 4 electrical acupuncture stimulator (this is no longer made) was used for Horses 1-4 and Horse 6; an AS SUPER 4 5 digital electric needle stimulator was used to treat
Horse 5 for all but the first treatment (Supplementary Item 1).
Crocodile clips from the lead were attached to each needle close to the skin to prevent 'drag' on the needle (Fig 1) . The battery-operated EA unit was switched on and the intensity of stimulation increased slowly in increments of 0.1 mA until the nostril started to twitch. This was independently controlled for the two frequency settings (2 and 80 Hz) with the CEFAR ACUS 4. With the AS SUPER 4 the intensity of both frequencies changes at the same time. Once the twitch was observed, the intensity was increased very slowly to a level where both the twitch of the 2 Hz and the tetanic spasm of the 80 Hz were visible but not causing the horse any discomfort (Supplementary Item 2). This was maintained for a period of 25 min. If the first visible twitch caused the horse's head to jerk rather than just a localised nostril twitch, the needle was considered to be too close to the infraorbital nerve. The current was reduced or switched off and the needle repositioned usually without the need to withdraw it completely. As the treatment progressed the intensity sometimes needed to be increased to maintain a constant level of twitch. On a small number of occasions, the stimulus caused a local twitch around the needle that did not extend to the muzzle region or only when the intensity was increased to a level above that considered acceptable. When this occurred, the intensity was reduced and the needle slowly withdrawn a little. This usually released the tip of the needle from within a band of fascia, and the muscle(s) started to contract freely. If the lower eyelid was seen to twitch or lacrimation occurred due to inadvertent stimulation of the facial nerve (CN VII) the needle was repositioned 1-2 cm more rostrally to avoid the possibility of corneal irritation.
For the first treatment session, the whole procedure was then repeated on the other side of the face. Thereafter, if the horse was settled, treatment of the second side commenced once the first side was underway. If necessary, the sedation was topped up before treatment of the second side.
At the completion of treatment, instructions for the immediate management of the horse were dependent on the weather and the known trigger factors of the individual horse, which were avoided as far as possible. Three of the horses were known to be sensitive to sunlight and the owners were asked to keep a UV light-blocking fly mask ) and nose net 6, 8, 9 , removing the mask only for competitions and jumping. Owners were also advised against trimming the whiskers, using a twitch or clipping the horse's face over the infraorbital nerve. Optimum fly control was advocated with the use of fly rugs, repellents and stabling in summer. A daily report was requested by email including the horse's name, the date, headshaking grades, weather conditions, exercise type and duration, plus any comments. Ridden work or driving could be undertaken the day following treatment unless the headshaking remained severe.
Horses responding to the first treatment were given a second treatment as soon as there was any sign of recurrence. Those that did not respond or showed short-lived improvement were given a second treatment 4-7 days after the first. Before each treatment, the horses were observed at exercise and graded by the author unless darkness or inclement weather prevented this. Horse 5 was examined by the author for the first treatment but was geographically too far away for follow up treatment sessions. For this case, the technique was demonstrated to two experienced equine veterinary surgeons from a referral practice who carried out treatment on the second side of the face under the author's guidance and then performed all subsequent procedures when requested by the author who was in daily communication with the horse's owner. When the horses were consistently scored at grade 0 for 3 weeks daily reporting was discontinued and owners were asked to make contact at the first sign of recurrence of clinical signs. The horses occasionally experienced a single day with mild signs before a further period of remission. They were treated when showing signs of headshaking for 2 consecutive days.
Results
Three mares and three geldings with an age range of 5-22 years were included in the study ( Table 1) . They had a clinical history of headshaking for between 3 weeks and 3 years. Horses 1 and 2 were seasonally affected during the spring and summer months; Horses 3-6 only started headshaking within the trial period, so any seasonality was unknown.
There was no resentment of the acupuncture needle placement and the procedure was well tolerated by the six horses and ponies. No serious adverse effects occurred.
An interesting variable was observed in that different muscles twitched with each horse and with the same horse on successive treatments. This is likely to be due to individual variations of the horse's anatomy and slight differences in the positioning of the needle. Twitches were variably observed in the levator labii maxillaris (Supplementary Item 3) , the levator nasolabialis (Supplementary Item 4) and orbicularis oris muscles (Supplementary Item 5). All of these receive most of their motor supply from the facial nerve and a small number of motor fibres in the infraorbital nerve. The muscle that was stimulated to contract did not appear to influence the outcome of treatment in this study but a twitch of the levator nasolabialis was the goal as affected horses selectively rub this area.
All six horses showed a reduction in the grade of headshaking and the treatment intervals for each horse are recorded in Table 4 . The daily grades of the horses as reported by the owners are shown in Figs 2-7. For Horses 4, 5 and 6 the headshaking grades at rest have also been shown as they influenced the timing of treatment. Median remission time for the first treatment was 5.5 days, (mean 7.6 days, range 0-13 days, n = 6), second treatment 8.5 days (mean 10.6 days, range 7-21 days, n = 6), third treatment 18 days (mean 28.8 days, range 6-71 days, n = 6), fourth treatment 47.5 days (mean 10 weeks, range 11 days-23 weeks, n = 6), fifth treatment 13 weeks 5 days (mean 18 weeks 5 days, range 5-46 weeks, n = 5), sixth treatment 24 days (mean 26 days, range 13-41 days, n = 3).
Horse 1 was used for competitive dressage. She had been seasonally affected for 3 years prior to the start of the study and was unrideable through the spring and summer months until late October. Throughout the study, she resumed work the day after each procedure and the treatment intervals were 13 days, 3 weeks, 7 weeks, 23 weeks and 21 weeks. In the 18-month period between her third treatment in May 2015 and the end of the trial in October 2016, she scored grade 0 apart from 9 days at grade 1 and one day at grade 2. Treatment 6 was given in May 2016 and following this she had shown no further clinical signs by the end of the study in October 2016, a period of 21 weeks (Fig 2) . She competed successfully in affiliated dressage competitions all year round throughout the 19-month trial period.
Horse 2, a driving pony, was first affected in 2014, between the months of June and November. The headshaking grades varied between 1 and 3 both in the stable and when driven. At the start of EA treatment in April 2015 she was graded at 2-3. (Supplementary Item 6) . Between treatments 1-5, given at intervals of 5 days, one week, 3 weeks, and 6 weeks the headshaking lessened but was not abolished. When driven she scored grade 1 on most days (Supplementary Item 7) . Treatment 5 was given on 26 June 2015 and she remained asymptomatic (grade 0) until mid-May 2016, an interval of 46 weeks. A 6th treatment was (Fig 3) . Horse 3 was used for eventing. He had been in his owner's possession for 2 years when he developed sudden onset headshaking at variable grades between 1 and 3 in May 2015. This persisted until his first treatment in August 2015. Treatment intervals were 6 days, 12 days, 10 weeks and 20 weeks (Supplementary Items 8 and 9) . He occasionally showed signs on a single day between treatments but this spontaneously resolved and his eventing career continued uninterrupted. At the end of the study period he had maintained grade 0 and not received a treatment for 6 months (Fig 4) .
Horse 4 developed clinical signs of headshaking in July 2015. It was well controlled with the use of a nose net but their use is prohibited in eventing under FEI rules. His signs were variable (grades 1-3) and made him unrideable at times. They were mild in the stable and exacerbated by exercise. He responded to treatment allowing him to be ridden and compete but still showed mild grade 1 signs (occasional tics) on some days in the stable and at exercise.
In March 2016 he became lame and received no further follow-up (Fig 5) .
Horse 5 was purchased to bring on for riding club activities in November 2014. He first showed signs of headshaking in September 2015 with variable signs ranging from grade 0 to 3 and was no longer ridden. At the first assessment in March 2016 he was not headshaking in the stable. On the lunge he constantly rubbed his nose along the ground or spontaneously burst into canter becoming distressed with violent vertical flicks of his head. This continued when brought back into the stable and sedated, making needle placement difficult. He responded to the EA with treatment intervals of 5 days, 8 days, 6 days, 7 weeks, 14 weeks and 3 weeks. In August 2016 the development of a pronounced firm swelling of his upper lip, thought to be due to a sting, coincided with a peak in HS grade 2 at rest (Fig 6) . During the trial period his training continued. He was the only horse in the study that would not tolerate a facemask or nose net during the period of treatment.
Horse 6 was the most severely affected; she started headshaking 3 weeks after purchase and would not tolerate anything touching her nose or muzzle. At the start of treatment on 16 June 2016 she presented as grade 3 in the stable and on the lunge (Supplementary Item 10) . The only short periods without any signs were momentarily when eating or when lying down in the stable. Following the first and second treatments there was an exacerbation of the clinical signs for 2-3 days. The first short period of complete remission occurred after the third treatment, scoring grade 0 for 3 consecutive days. Following the fourth EA session given 22 days after the commencement of treatment the mare was ridden for the first time. A longer period of remission occurred after the fifth treatment lasting 36 days at grade 0 (Supplementary Item 11). Treatment 6 was effective for 2 weeks and treatment 7 for just 5 days. Following an eighth treatment, the mare remained asymptomatic for the 3 weeks until the end of the study period (Fig 7) and a further 5 weeks thereafter. Since the fifth treatment the mare has been ridden regularly and lightly competed in riding club activities.
Horses 1, 2, 3, 5 and 6 continue to be monitored as part of the ongoing study.
Discussion
Case selection was important as this treatment is for cases with suspected trigeminal neuralgia rather than head shakers that are suffering from other underlying pathology (Lane and Mair 1987) . Whilst it is difficult to be categorical as none of the horses in the study underwent posterior ethmoidal analgesia or nerve conduction studies, both the referring veterinary surgeons and the author considered TMHS the most likely diagnosis. The owners were offered a full diagnostic work-up including local anaesthesia and a computed tomography scan, but five of the six declined due to the cost.
The trigeminal nerve is the largest of the cranial nerves. It is divided into ophthalmic, maxillary and mandibular branches. The maxillary division supplies sensory innervation to the rostral maxillary teeth, the upper lip, the nose and part of the maxillary sinus. The infraorbital nerve is a branch of the maxillary trunk. It traverses the infraorbital canal and emerges through the infraorbital foramen where it divides into nasal and maxillary labial branches. These divide again and supply sensation to the upper lip, nostril, alveolar periosteum and gums (Sisson and Grossman 1975) . Horses affected by TMHS have hypersensitive trigeminal nerves with a lower threshold for activation . However, the seasonality of clinical signs and periods of remission imply a reversible functional abnormality (Pickles et al. 2014 ) and thus that treatment should be directed towards neuromodulation rather than destruction of the nerve. On gross pathological and histological examination of horses subjected to euthanasia for TMHS, no abnormalities of the infraorbital nerve have been found (Newton et al. 2000) .
The strength of stimulation depended on two factors: the strength of the current and the proximity of the needle to the nerve. It was important to increase the intensity slowly and incrementally in order not to cause the patient discomfort by overstimulation of the nerve.
The treatment time was initially 25 min for each side of the face. It is suggested that the time is reduced to 20 min with a reduced stimulus intensity giving a smaller muscle twitch in horses that have aggravated clinical signs after the procedure in the early stages of the treatment programme (Horse 6).
The use of a face mask and nose net was considered to be an important part of the management routine when combined with EA. Removing the face mask was a definite HS trigger for Horses 2, 3 and 6. A possible criticism of this study is that the horses were assessed on a daily basis by the owner and at treatment sessions by the author rather than a blinded assessment by a panel of experts. In a previous study Mair et al. (1992) suggested that owners are reliable assessors in this type of study. Owners spend the most time with the horse and observe it in its usual surroundings. Moving them to a referral centre for assessment could modify their behaviour and give a false impression of their headshaking status. The four possible grades had distinct descriptions, making grade selection for the owners relatively straightforward ( Table 3) .
The use of different stimulators unavoidably occurred, as the CEFAR ACUS 4 is no longer available to purchase. The CEFAR ACUS 4 was set on 80 Hz as a high frequency and the AS SUPER 4 on 100 Hz. This is unlikely to affect the outcome as Horse 5 responded to treatment with the latter and the author also tested it for the May 2016 treatment of Horse 1 with a positive result. Further studies could be carried out to investigate the effects of using different frequencies and pulse durations.
It is possible that more than one sensory branch of the trigeminal nerve is involved (Newton et al. 2000) and neuromodulation of the mandibular or ophthalmic branches of the nerve with EA is now being performed in ongoing studies by the author. This offers the potential for treatment in cases where stimulation of the infraorbital nerve alone does not provide adequate relief.
Horse 6 was the most severely affected, with such frenzied headshaking and nose rubbing at the start of treatment that euthanasia was considered. There were a number of management changes and behavioural issues that may have contributed to her short response time of just 5 days to treatment 7. She was turned out into the sunshine immediately after this treatment and within the same week there was a change of field, bedding, bit, bridle, field companion and she was occasionally ridden without a face mask. She took an intense dislike to the new companion. This suggests that careful management of affected horses is necessary alongside any treatment of TMHS.
Summary
In this case series, EA worked effectively to reduce HS in all six of the horses. The equipment is easily portable and can be used in the stable yard, eliminating the need for these distressed horses to travel. It is a safe procedure that does not require the hospital facilities and expensive equipment that is routinely used for percutaneous electrical nerve stimulation (PENS). With some training in the technique EA can be performed within ambulatory equine practice, making it widely available to affected horses.
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